drugset / Trial / NCT04136353
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
Phase 3
Active not recruiting
1100 enrolled
University of Sydney
Australian and New Zealand Urogenital and Prostate Cancer Trials Group · collabBayer · collabCanadian Cancer Trials Group · collabCancer Trials Ireland · collabMemorial Sloan Kettering Cancer Center · collabProstate Cancer Clinical Trials Consortium · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the effectiveness of darolutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate cancer at very high risk of recurrence.
Timeline
- Start
- 2020-03-31
- Primary completion
- 2028-01-31
- Completion
- 2028-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darolutamide | Other / unclassified | 600 mg | Oral |